Primary hyperaldosteronism in a patient with end-stage renal disease.
Kazory
Amir
A
Division of Nephrology, University of Florida, 1600 SW Archer Rd, Gainesville, FL 32610, USA. amir.kazory@medicine.ufl.edu
Weiner
I David
ID
D000450:Aldosterone / Q000097:blood; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D001794:Blood Pressure; D005500:Follow-Up Studies; D017328:Fosinopril / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D006929:Hyperaldosteronism / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D006973:Hypertension / Q000209:etiology* / Q000503:physiopathology; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D006435:Renal Dialysis; D012083:Renin / Q000097:blood; D013148:Spironolactone / Q000627:therapeutic use
D000806:Angiotensin-Converting Enzyme Inhibitors; D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D000450:Aldosterone; D012083:Renin; D017328:Fosinopril